Floris Imhann

Floris Imhann

Auto-generated profile, based on publicly available information

Floris Imhann

Department of Genetics, University of Groningen and University Medical Center Groningen, Groningen, The Netherlands

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 December 2018 in Nature Microbiology
Verified
Journal Article
Closed access
PDF file
EFEric A. Franzosa
Eric A. Franzosa
ASAlexandra Sirota-Madi
Alexandra Sirota-Madi
JAJulian Avila-Pacheco
Julian Avila-Pacheco
NFNadine Fornelos
Nadine Fornelos
HHHenry J. Haiser
Henry J. Haiser
RXRamnik J. Xavier
Ramnik J. Xavier

19 December 2018 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
AVArnau Vich Vila
Arnau Vich Vila
FIFloris Imhann
Floris Imhann
VCValerie Collij
Valerie Collij
SJSoesma A. Jankipersadsing
Soesma A. Jankipersadsing
TGThomas Gurry
Thomas Gurry
RWRinse K. Weersma
Rinse K. Weersma
Differences in gut microbiota composition and function were observed between patients with inflammatory bowel disease or irritable bowel syndrome.

29 October 2018 in Gut Microbes
Verified
Journal Article
Open access
TSTrishla Sinha
Trishla Sinha
AVArnau Vich Vila
Arnau Vich Vila
SGSanzhima Garmaeva
Sanzhima Garmaeva
SJSoesma A. Jankipersadsing
Soesma A. Jankipersadsing
FIFloris Imhann
Floris Imhann
AZAlexandra Zhernakova
Alexandra Zhernakova
Several gastrointestinal diseases show a sex imbalance, although the underlying (patho)physiological mechanisms behind this are not well understood. The gut microbiome may be involved in this process, forming a complex interaction with host immune system, sex hormones, medication and other environmental factors. Here we performed sex-specific analyses of fecal microbiota composition in 1135 individuals from a population-based cohort. The overall gut microbiome composition of females and males was significantly different (p = 0.001), with females showing a greater microbial diversity (p = 0.009). After correcting for the effects of intrinsic factors, smoking, diet and medications, female hormonal factors such as the use of oral contraceptives and undergoing an ovariectomy were associated with microbial species and pathways. Females had a higher richness of antibiotic-resistance genes, with the most notable being resistance to the lincosamide nucleotidyltransferase (LNU) gene family. The higher abundance of resistance genes is consistent with the greater prescription of the Macrolide-Lincosamide-Streptogramin classes of antibiotics to females. Furthermore, we observed an increased resistance to aminoglycosides in females with self-reported irritable bowel syndrome. These results throw light upon the effects of common medications that are differentially prescribed between sexes and highlight the importance of sex-specific analysis when studying the gut microbiome and resistome.

8 January 2019 in BMC Gastroenterology
Verified
Journal Article
Open access
PDF file
FIFloris Imhann
Floris Imhann
KVK. J. Van der Velde
K. J. Van der Velde
RBR. Barbieri
R. Barbieri
RAR. Alberts
R. Alberts
MVM. D. Voskuil
M. D. Voskuil
RWR. K. Weersma
R. K. Weersma
Inflammatory bowel disease (IBD) is a chronic complex disease of the gastrointestinal tract. Patients with IBD can experience a wide range of symptoms, but the pathophysiological mechanisms that cause these individual differences in clinical presentation remain largely unknown. In consequence, IBD is currently classified into subtypes using clinical characteristics. If we are to develop a more targeted treatment approach, molecular subtypes of IBD need to be discovered that can be used as new drug targets. To achieve this, we need multiple layers of molecular data generated from the same IBD patients. We initiated the 1000IBD project ( https://1000ibd.org ) to prospectively follow more than 1000 IBD patients from the Northern provinces of the Netherlands. For these patients, we have collected a uniquely large number of phenotypes and generated multi-omics profiles. To date, 1215 participants have been enrolled in the project and enrolment is on-going. Phenotype data collected for these participants includes information on dietary and environmental factors, drug responses and adverse drug events. Genome information has been generated using genotyping (ImmunoChip, Global Screening Array and HumanExomeChip) and sequencing (whole exome sequencing and targeted resequencing of IBD susceptibility loci), transcriptome information generated using RNA-sequencing of intestinal biopsies and microbiome information generated using both sequencing of the 16S rRNA gene and whole genome shotgun metagenomic sequencing. All molecular data generated within the 1000IBD project will be shared on the European Genome-Phenome Archive ( https://ega-archive.org , accession no: EGAS00001002702). The first data release, detailed in this announcement and released simultaneously with this publication, will contain basic phenotypes for 1215 participants, genotypes of 314 participants and gut microbiome data from stool samples (315 participants) and biopsies (107 participants) generated by tag sequencing the 16S gene. Future releases will comprise many more additional phenotypes and -omics data layers. 1000IBD data can be used by other researchers as a replication cohort, a dataset to test new software tools, or a dataset for applying new statistical models. We report on the establishment and future development of the 1000IBD project: the first comprehensive multi-omics dataset aimed at discovering IBD biomarker profiles and treatment targets.

10 April 2019 in Nature Microbiology
Verified
Journal Article
Open access
PDF file
EFEric A. Franzosa
Eric A. Franzosa
ASAlexandra Sirota-Madi
Alexandra Sirota-Madi
JAJulian Avila-Pacheco
Julian Avila-Pacheco
NFNadine Fornelos
Nadine Fornelos
HHHenry J. Haiser
Henry J. Haiser
RXRamnik J. Xavier
Ramnik J. Xavier
In the Supplementary Tables 2, 4 and 6 originally published with this Article, the authors mistakenly included sample identifiers in the form of UMCGs rather than UMCG IBDs in the validation cohort; this has now been amended.

1 April 2016 in Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease
Verified
Journal Article
Closed access
ARAnouk Regeling
Anouk Regeling
FIFloris Imhann
Floris Imhann
HVHaukeline H. Volders
Haukeline H. Volders
TBT. Blokzijl
T. Blokzijl
VBVincent W. Bloks
Vincent W. Bloks
KFKlaas Nico Faber
Klaas Nico Faber